NASD · Healthcare · Biotechnology · United Kingdom
Autolus Therapeutics plc ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing T cell therapies for cancer and autoimmune diseases using proprietary programming technologies. The company engineers targeted therapies designed to recognize and eliminate disease cells. Its lead product, AUCATZYL, treats adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia and has been approved in the United States and United Kingdom.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Autolus Therapeutics plc ADR stock.
Overvalued: intrinsic value $0.43 per share, market price $1.52, margin of safety -254.9% (as of 2026-10-30).
A 2.4x revenue multiple, discounted for its losses, values the shares at $0.43; the price of $1.52 is 255% above that value.
Leak Score: 45/100 on 8 of 12 signals (On Watch).
75 more in this industry show a wider margin of safety.
AUTL is overvalued (as of the 2026-10-30 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $0.43; the price of $1.52 is 255% above that value.
$0.43 per share (as of the 2026-10-30 close), against a market price of $1.52. That is a margin of safety of -254.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
45 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.